QR-koodi

The safety and efficacy of dabrafenib plus trametinib for patients with brain metastatic melanoma: a systematic review and meta-analysis

Abstract Background Brain metastases (BM) are common complications of metastatic cancer and typically occur in patients with melanoma. This study aims to investigate the dabrafenib plus trametinib for patients diagnosed with melanoma brain metastasis (MBM). Method This review adhered to the Preferre...

Täydet tiedot

Tallennettuna:
Päätekijät: Mohammad Amin Habibi, Mohammad Sina Mirjani, Bardia Hajikarimloo, Mohsen Dashti, Afsaneh Ghasemzadeh, Seyed Hesam Hojjat, Mohammad Shahir Eftekhar, Kosar Doraghi, Yalda Ghazizadeh, Fateme Aghaei, Shaghayegh Karami, Mehrshad Edalat, Farhang Rashidi, Sajjad Ahmadpour, Sina Ahmadi
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer 2025-06-01
Sarja:Discover Oncology
Aiheet:
BRAF inhibitor
Dabrafenib
MEK inhibitor
Melanoma
Melanoma brain metastasis
Trametinib
Linkit:https://doi.org/10.1007/s12672-025-02778-8
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia